CRTX

Crism Therapeutics Corporation

Health Care First-pass screen £6.60m

200/1000 Overall fit

AI beneficiary 35% 15

Operating leverage 25% 15

Valuation 25% 30

Downside protection 15% 20

First-pass take

Pre-clinical biotech with ChemoSeed for glioblastoma/prostate cancer; zero AI exposure; zero 2024 revenue; £933k annual burn (£732k decline by May 2025); explicit going concern warning; requires 2025 equity dilution.

Flags

going-concernpre-clinicalcash-burnregulatory-riskmicro-cap